Unknown

Dataset Information

0

Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study.


ABSTRACT:

Aims

Cardiac resynchronisation therapy (CRT) is effective treatment for selected patients with heart failure (HF) but has ~30% non-response rate. We evaluated whether specific biomarkers can predict outcome.

Methods

A prospective single-centre pilot study of consecutive unselected patients undergoing CRT for HF between November 2013 and December 2015 evaluating cardiac extracellular matrix biomarkers and micro-ribonucleic acid (miRNA) expression before and after CRT assessing ability to predict functional response and survival. Each underwent three assessments (pre-implant, 6  weeks and 6  months postimplant) including: New York Heart Association (NYHA) class, echocardiography, electrocardiography, 6  min walk test (6MWT), Minnesota Living with Heart Failure Questionnaire (MLHFQ) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP). Plasma markers of cardiac fibrosis assessed were: N-terminal pro-peptides of collagen I and III, collagen I C-terminal telopeptides (CTx) and matrix metalloproteinases (MMP-2 and MMP-9) as well as a panel of miRNAs (miRNA-21, miRNA-30d, miRNA-122, miRNA-133a, miRNA-210 and miRNA-486).

Results

A total of 52 patients were recruited; mean age (±SD) was 72.4±9.4 years; male=43 (82.7%), ischaemic aetiology=30 (57.7%), mean QRS duration=166.4±23.5  ms, left bundle branch block (LBBB) morphology = 39 (75.0%), mean NYHA=2.7±0.6, 6MWT=238.8±130.6  m, MLHFQ=46.4±21.3  and left ventricular ejection fraction (LVEF)=24.3%±8.0%. Mean follow-up=1.7±0.3  and 5.8±0.7 months. There were 27 (55.1%) functional responders (3 no definable 6-month response; 2 missed assessments and 1 long-term lead displacement). No marker predicted response, however, CTx and LBBB trended most towards predicting functional response.

Conclusion

No specific biomarkers reached significance for predicting functional response to CRT. CTx showed a trend towards predicting response and warrants further study.

Trial registration number

NCT02541773.

SUBMITTER: McAloon CJ 

PROVIDER: S-EPMC6196945 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF study.

McAloon Christopher J CJ   Barwari Temo T   Hu Jimiao J   Hamborg Thomas T   Nevill Alan A   Hyndman Samantha S   Ansell Valerie V   Musa Anntoniette A   Jones Julie J   Goodby Julie J   Banerjee Prithwish P   O'Hare Paul P   Mayr Manuel M   Randeva Harpal H   Osman Faizel F  

Open heart 20181018 2


<h4>Aims</h4>Cardiac resynchronisation therapy (CRT) is effective treatment for selected patients with heart failure (HF) but has ~30% non-response rate. We evaluated whether specific biomarkers can predict outcome.<h4>Methods</h4>A prospective single-centre pilot study of consecutive unselected patients undergoing CRT for HF between November 2013 and December 2015 evaluating cardiac extracellular matrix biomarkers and micro-ribonucleic acid (miRNA) expression before and after CRT assessing abil  ...[more]

Similar Datasets

| S-EPMC6752801 | biostudies-literature
| S-EPMC6702464 | biostudies-literature
| S-EPMC9312363 | biostudies-literature
| S-EPMC4656051 | biostudies-literature
| S-EPMC10440957 | biostudies-literature
| S-EPMC5129079 | biostudies-literature
| S-EPMC10689176 | biostudies-literature
| S-EPMC8160050 | biostudies-literature
| S-EPMC10745247 | biostudies-literature
| S-EPMC4711514 | biostudies-literature